A Comparison of the Roche Cobas HPV Test with the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes

Archives of Pathology and Laboratory Medicine

Volumn 140, Issue 2, 2016, Pages 153-157

  Levi, Angelique W ^a   Bernstein, Jane I ^a,b   Hui, Pei ^a   Duch, Kara ^a   Schofield, Kevin ^a   Chhieng, David C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AmeriPath Southwest Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

COMPARATIVE STUDY; FEMALE; GENETICS; GENOTYPE; HUMAN; IN SITU HYBRIDIZATION; MOLECULAR DIAGNOSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; VAGINA SMEAR;

DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; IN SITU HYBRIDIZATION; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; VAGINAL SMEARS;

EID: 84957941720     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2015-0027-OA     Document Type: Article

References (24)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4): 244-265.
2. Bernard HU, Burk RD, Chen Z, Van Doorslaer K, Hausen H, De Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70-79.
3. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-part B: Biological agents. Lancet Oncol. 2009;10(4):321-322.
4. Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-527.
5. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: Addressing the limits of epidemiology at the borderline. Infect Agents Cancer. 2009;4:8.
6. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095-1101.
7. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357(16):1579-1588.
8. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197(4):346-355.
9. Gage JC, Sadorra M, Lamere BJ, et al. Comparison of the cobas human papillomavirus (HPV) test with the Hybrid Capture 2 and Linear Array HPV DNA tests. J Clin Microbiol. 2012;50(1):61-65.
10. Wong AA, Fuller J, Pabbaraju K, Wong S, Zahariadis G. Comparison of the Hybrid Capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium. J Clin Microbiol. 2012;50(1):25-29.
11. Lindemann ML, Dominguez MJ, De Antonio JC, et al. Analytical comparison of the cobas HPV test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J Mol Diagn. 2012;14(1):65-70.
12. Park Y, Lee E, Choi J, Jeong S, Kim HS. Comparison of the Abbott RealTime high-risk human papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J Clin Microbiol. 2012; 50(7):2359-2365.
13. Castle PE, Sadorra M, Lau T, Aldrich C, Garcia FA, Kornegay J. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J Clin Microbiol. 2009;47(10):3344-3347.
14. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL. High-risk human papillomavirus testing in women with ASC-US cytology: Results from the ATHENA HPV study. Am J Clin Pathol. 2011;135(3):468-475.
15. Cobas HPV test [package insert]. Branchburg, NJ: Roche Molecular Systems Inc; 2011.
16. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-310.
17. Clinical Laboratory Improvement Amendments. 42 CFR §493.1253 (2003).
18. College of American Pathologists. Microbiology checklist. Chicago, IL; College of American Pathologists: 2012.
19. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: Design, methods, and baseline results. Am J Obstet Gynecol. 2012;206(1):46.e1-46.e11.
20. Ko V, Tambouret RH, Kuebler DL, Black-Schaffer WS, Wilbur DC. Human papillomavirus testing using Hybrid Capture II with SurePath collection: Initial evaluation and longitudinal data provide clinical validation for this method. Cancer. 2006;108(6):468-474.
21. Castle PE, Schiffman M, Burk RD, et al. Restricted cross-reactivity of Hybrid Capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1394-1399.
22. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of Hybrid Capture 2. J Clin Microbiol. 2008;46(8):2595-2604.
23. Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol. 2002;25(suppl 3):S89-S97.
24. Sandri MT, Lentati P, Benini E, et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol. 2006;44(6):2141-2146.